Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Mars Petcare acquires AniCura
Mandate

Mars Petcare acquires AniCura

June 13, 2018 M&A

Vinge advises Fidelio Capital in connection with entering into an agreement with Mars Petcare regarding Mars Petcare's acquisition of AniCura.

AniCura was founded in 2011 by Fidelio Capital and The Animal Hospital Foundation in Greater Stockholm through the first merger of companion animal hospitals in the Nordic region. Since then the company grown to become one of Europe’s leading providers of high-quality veterinary care for companion animals and today AniCura has more than 4,000 veterinary professionals who provides modern, high-quality veterinary care for pets at 200 European locations across seven European countries. In 2014, Nordic Capital joined the company as a majority owner, with Fidelio Capital remaining as a significant shareholder. The acquisition is subject to customary regulatory approvals.

Vinge’s team consisted of, among others, Jonas Bergström and Joacim Rydergård.
 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026